# Semaglutide trial populations

> Semaglutide | Tailor Made Peptides Review — Semaglutide in Tailor Made Peptides Review: weight, heart and kidney results, with the different people enrolled in each trial.

A medicine can travel between several questions. The people in the weight, heart and kidney studies explain why the answers need their own settings.

## Weight: STEP 1

Semaglutide [copies GLP-1, a hormone involved in appetite and blood-sugar control](https://pubmed.ncbi.nlm.nih.gov/34305810/). Changes to the molecule help it remain in blood longer than the natural hormone. It is a prescription medicine; the research here concerns the preparations actually studied.

The [STEP 1 weight trial](https://pubmed.ncbi.nlm.nih.gov/33567185/) enrolled adults with overweight or obesity without diabetes. After 68 weeks, mean weight change was −14.9% with semaglutide and −2.4% with placebo. I admire that change, with no expectation that the mean could forecast every reader's response. Starting health and the ability to continue treatment still matter.

## Heart disease: SELECT

The [SELECT participants already had cardiovascular disease](https://pubmed.ncbi.nlm.nih.gov/37952131/), along with overweight or obesity, and did not have diabetes. The study counted cardiovascular death, non-fatal heart attack and non-fatal stroke as a combined outcome. Semaglutide lowered the risk of that combined outcome compared with placebo.

I put particular value on this kind of result because an actual illness was counted. At the same time, the entry conditions do real work: the finding concerns people with established cardiovascular disease. Extending it to someone with a very different starting risk requires another judgment.

> SELECT began with existing cardiovascular disease. STEP 1 began with a weight question.

## Kidney disease: FLOW

In [FLOW, participants had type 2 diabetes and chronic kidney disease](https://pubmed.ncbi.nlm.nih.gov/38785209/). The combined outcome included kidney failure, major loss of kidney function, and kidney or cardiovascular death. Semaglutide reduced that outcome compared with placebo.

The heart and kidney papers give semaglutide a broader story than a changing waistline. I prize the specificity here: an organ, an existing illness, an outcome that matters. Combining events makes a trial workable, but it also means the headline result cannot tell us the effect on every component separately.

![A heart model and a kidney model on a pale teaching table](images/heart-kidney-casts.webp)

*Illustrative anatomical models for the separate heart and kidney outcome questions. The trials enrolled different populations.*

## Semaglutide safety

The [semaglutide safety review](https://pubmed.ncbi.nlm.nih.gov/34305810/) describes nausea, vomiting, diarrhea and constipation, often transient, as well as increased gallbladder disease. Pancreatitis remains a warning. Thyroid-tumor findings came from rodents; the available human evidence leaves the cancer question unsettled. Rapid improvement in blood sugar can also worsen existing diabetic eye disease.

Community accounts describe quieter appetite, changed cravings, burping, tiredness and hair shedding. These are anecdotal accounts, not clinical evidence, and they cannot establish the cause or frequency of an experience. A vivid account can be hard to set aside; I'd hesitate to use it as a measure of anybody else's risk.

For a direct weight comparison with another medicine, the [tirzepatide notes](/tirzepatide) examine the trials that actually put both treatments into the same study. The fit question there includes the treatment regimens and side effects as well as the final averages.

---

An independent review of metabolic-response distributions and their evidence limits—not a clinic, vendor, or individualized protocol.